Zealand Pharma A/s · OMXCOP:ZEAL
Zealand Pharma A/s — H1 2017 Earnings Presentation
18 slides from Zealand Pharma A/s's earnings presentation, Aug 24, 2017
Slide 1: Forward-looking statements
Forward-looking statements This presentation contains information pertaining to Zealand Pharma A/S (“Zealand"). Neither Zealand nor its management, directors, employees or representatives make any representation or warranty, express or implied, as to the accuracy or completeness of any of the inform
Slide 2: Advanced pipeline focused on speciality gastrointestinal and metabolic diseases
Advanced pipeline focused on speciality gastrointestinal and metabolic diseases Type 2 diabetes drug* partnered with Sanofi launched in the U.S. and EU in 2017 New combination treatment addressing large market Key portfolio asset for Sanofi One Phase 3 program Two Phase 2 programs – One approaching
Slide 3: Highlights
Highlights Financial highlights Business highlights Q2 Business highlights for the period after H1 financial results Nasdaq listing Financial guidance
Slide 4: Financial highlights for H1 2017
Financial highlights for H1 2017 Revenue DKK 88.4 million/ USD 13.6 million Cash position DKK 308.3 million USD 47.3 million 30 June, 2017 Net operating expenses DKK 174.8 million/ USD 23.3 million Net result DKK -120.0 million USD -18.4 million US IPO Gross proceeds DKK 566 million USD 90 million 1
Slide 5: Business highlights for Q2 2017
Business highlights for Q2 2017 Glepaglutide Glepaglutide met primary endpoint in Phase 2 clinical trial for short bowel syndrome Dasiglucagon Positive results from two Phase 2a trials for use in a dual hormone pump system Orphan designation for congenital hyperinsulinism (CHI) obtained in the EU He
Slide 6: Business highlights for the period thereafter
Business highlights for the period thereafter Dasiglucagon First patients dosed in Phase 3 trial for severe hypoglycemia in diabetes Orphan designation for congenital hyperinsulinism (CHI) obtained in the U.S. Boehringer Ingelheim First patients dosed in Phase 1 trial in amylin program partnered wit
Slide 7: H1 2017 financial results
H1 2017 financial results Income statement (DKK '000) 2017 2016 2016 H1 H1 Full year Revenue (royalties and milestone payments) 88,421 14,686 234,778 Royalty expenses -11,712 -1,764 -31,459 Research and development expenses -152,145 -139,957 -268,159 Administrative expenses -23,055 -26,531 -52,503 O
Slide 8: Listing on the Nasdaq Global Select Market in the U.S.
Listing on the Nasdaq Global Select Market in the U.S. 5,031,250 shares issued as ADS’s, trading on Nasdaq Global Select Market in New York A total of 30,718,652 shares 16.4% are issued as ADS’s 83.6% on the Copenhagen stock exchange Total gross proceeds amount to DKK 566 million / USD 90 million
Slide 9: Financial guidance for 2017 unchanged
Financial guidance for 2017 unchanged DKK USD Revenue from milestone payments* 100 million** 15 million** Royalty revenue from Sanofi collaboration* No guidance Net operating expenses 390-410 million 60-63 million Operating loss before royalty income and royalty expenses 290-310 million 45-48 millio
Slide 10: Portfolio update
Portfolio update Soliqua® 100/33 update Pipeline Glepaglutide Dasiglucagon Orphan designation of dasiglucagon Boehringer Ingelheim Summary Q&A
Slide 11: Soliqua 100/33 is a strategic priority product for Sanofi with growing prescriptions
Soliqua® 100/33 is a strategic priority product for Sanofi with growing prescriptions Strong commitment by Sanofi Soliqua® 100/33 is one of Sanofi’s six priority products, with projected combined revenues of USD 12-14 billion in 2020** Available in U.S. pharmacies just six weeks after approval As th
Slide 12: Important milestones in 2017 for our product candidates
Important milestones in 2017 for our product candidates Product candidate Indication Development stage Preclinical Phase 1 Phase 2 Phase 3 Registration 2017 milestone Glepaglutide*1 GLP-2 analog Dasiglugacon*1 Rescue pen Amylin analog2 GLP1-GLU2 dual agonist Short bowel syndrome Acute, severe hypogl
Slide 13: Glepaglutide met Phase 2 primary end-point of reduction in fecal wet weight
Glepaglutide met Phase 2 primary end-point of reduction in fecal wet weight Increases in gastrointestinal fluid and energy absorption observed Observed to be safe and well tolerated in the trial “This is the most comprehensive Phase 2 trial conducted to date in patients with short bowel syndrome and
Slide 14: Phase 2a trial results support development of dasiglucagon in the iLet pump
Phase 2a trial results support development of dasiglucagon in the iLet™ pump for type 1 diabetes Pharmacokinetic and pharmacodynamics profile of concentrated formulation Adequate blood glucose increases in response to micro doses of dasiglucagon No safety issues observed Positive results reported1 H
Slide 15: Orphan designation of dasiglucagon for congenital hyperinsulinism obtained in EU and U.S.
Orphan designation of dasiglucagon for congenital hyperinsulinism (CHI) obtained in the EU and the U.S. Disease Congenital hyperinsulinism (CHI) is a rare condition associated with high levels of insulin in the blood, leading to severe hypoglycemia in newborns and children Repeated episodes of low b
Slide 16: Boehringer Ingelheim programs – two product candidates on obesity/type 2 diabetes
Boehringer Ingelheim programs – two product candidates on obesity/type 2 diabetes Dasiglucagon First patients dosed in Phase 1 trial in GLP1/glucagon program on obesity/diabetes First patients dosed in Phase 1 trial in amylin program on obesity/diabetes GLP-1/glucagon dual-acting agonist Long-acting
Slide 17: Q&A - Upcoming events
Q&A - Upcoming events September 11-13, 2017 Morgan Stanley Global Healthcare Conference, New York September 19, 2017 InvestorDagen, Copenhagen September 27, 2017 ABGSC Small & Mid Cap efterårsseminar, Copenhagen S2:00pm – 3:00pm14:00 – 15:00 eight one media November 15, 2017 Jefferies Healthcare Con
Slide 18: Upcoming events in 2017
Q&A Upcoming events in 2017 Morgan Stanley Global Healthcare Conference, New York 11-13 September ABGSC Small and Midcap seminar, Copenhagen 27 September Jefferies Healthcare Conference, London 15 November BryanGarnier Healthcare Conference, Paris 16 November Citi Global Healthcare Conference, New Y